Friday a High Wave was formed. This implies a loss of sense of direction and that there is a great amount of indecision in the market. Bears are seemingly fatigued after consolidation and a bullish pattern seems to be forming. 60 million volume surges typically have reason and follow later "Large gains" bears would be well advised to buy to cover and go long or sit this one out.
ACAD's pimavanserin drug = first true Parkinson's disease psychosis treatment. The market will rapidly change towards a more bullish perspective on ACAD due to the recent results, which prove that the drug actually works! The drug is the company's most advanced and if approved currently has no competition in the marketplace. Those who were treated with pimavanserin, a 5.79-point reduction in psychotic behavior was observed, compared to a 2.73-point reduction in the control group. These results are statistically significant!
Acadia's run looks to be well deserved and will continue.
This review establishes an opinion of: MARKET OUTPERFORM price target $30 for those with patience.
Investors will probably agree with this review using their due diligence/fact checking.
Redstenox, I love you for such an admiration of Pimavanserin. I was in at $2.16 and wished I had more money to go all in as I was so convinced that the phase 3 was going to be very positive and I was right. Hey, Pima is good for the investors and patients who are suffering for the remaining years of their lives. They shouldn't be suffering like. I hope Pima will be the first-in class drug to treat PD. I love to buy more if I have more money and hold until FDA approves this damn good drug for mankind.